Pharmaceuticals, Biotechnology and Life Sciences
Three of Europe’s top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi <SASY.PA> and Roche <ROG.S> likely to win approvals for two new products, while GlaxoSmithKline <GSK.L> braces for a potential generic rival.
Teva Pharmaceutical Industries <TEVA.TA> may fire as many as 6,000 workers worldwide as part of a multi-year efficiency plan, Israel’s Calcalist news website reported on Thursday.
Futura medical, healthcare company focused on advanced transdermal technology, has announced its preliminary results for the year 2016.
A major research has been initiated, which will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.
Alcon, a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens (IOL) with Activefocus optical design for patients undergoing cataract surgery who choose to address their astigmatism and presbyopia at the same time.
Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, has entered into a global strategic services agreement with QuintilesIMS, a provider of biopharmaceutical development and commercial outsourcing services.
The U.S. Food and Drug Administration has approved Newron Pharmaceuticals’s Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa.
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie, …
Novartis’s acute heart failure (AHF) drug study did not meet its primary endpoint of reduction in cardiovascular death through Day 180 or reduced worsening heart failure through Day five when added to standard therapy
Venn Life Sciences, a Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has reported profit of €0,5 million for the 2016.